Acera Surgical

Executive Summary

Acera Surgical is a privately held bioscience company based in St. Louis, Missouri, founded in 2015. The company specializes in developing and commercializing fully synthetic, electrospun nanofiber matrices that mimic the structure of the human extracellular matrix. Its lead product, Restrata, is a resorbable scaffold approved for surgical and traumatic wound management, facilitating soft tissue repair and regenerative healing. By leveraging advanced electrospinning technology, Acera's materials offer a consistent, off-the-shelf alternative to biologic grafts, reducing variability and potential immunogenicity. The platform has potential applications across multiple surgical specialties, including hernia repair, plastic surgery, and orthopedic soft tissue reinforcement. Acera Surgical operates in the regenerative medicine market, which is experiencing robust growth driven by an aging population and increasing demand for advanced wound care solutions. The company has secured regulatory clearances for Restrata in the U.S., but its commercial traction remains early-stage given its private status. Key challenges include scaling manufacturing, gaining adoption among surgeons, and competing with established players like Integra LifeSciences and Gore Medical. However, Acera's unique fully synthetic approach could differentiate it if clinical outcomes prove superior. The company's future depends on expanding indications, building clinical evidence, and securing strategic partnerships to drive commercialization.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for hernia repair indication70% success
• Q2 2027Publication of pivotal clinical study results on Restrata in chronic wounds65% success
• Q3 2026Strategic partnership or distribution agreement with a major medical device company60% success